TDMS Study 05210-04 Pathology Tables
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
CORE STUDY
Facility: I. I. T. Research Institute
Chemical CAS #: 100-41-4
Lock Date: 10/02/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 75 PPM 250 750
PPM PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 5 6 1 4
Natural Death 9 6 8 9
Accidently Killed 1 1
Survivors
Terminal Sacrifice 34 38 40 37
Natural Death 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (48) (48) (50) (50)
Gallbladder (44) (44) (44) (46)
Intestine Large, Rectum (49) (48) (49) (47)
Intestine Large, Cecum (49) (47) (48) (44)
Intestine Small, Duodenum (45) (48) (47) (46)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (46) (46) (46) (45)
Intestine Small, Ileum (47) (47) (47) (46)
Liver (50) (50) (50) (50)
Cholangiocarcinoma 1 (2%)
Fibrosarcoma, Metastatic, Pancreas 1 (2%)
Hemangioma 1 (2%)
Hepatocellular Carcinoma 7 (14%) 4 (8%) 3 (6%) 10 (20%)
Hepatocellular Carcinoma, Multiple 2 (4%)
Hepatocellular Adenoma 6 (12%) 8 (16%) 9 (18%) 12 (24%)
Hepatocellular Adenoma, Multiple 1 (2%) 3 (6%) 4 (8%)
Pancreas (50) (50) (50) (49)
Fibrosarcoma 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (49) (48) (50)
Squamous Cell Papilloma 1 (2%) 2 (4%) 1 (2%) 1 (2%)
Stomach, Glandular (50) (49) (48) (50)
Serosa, Sarcoma, Metastatic, Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (46) (48) (48) (50)
Adventitia, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
Heart (50) (49) (50) (50)
Page 2
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 75 PPM 250 750
PPM PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM - cont
Fibrosarcoma, Metastatic, Pancreas 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (47) (50) (50) (49)
Adenoma 1 (2%)
Adrenal Medulla (47) (50) (50) (49)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (50) (50) (50) (49)
Adenoma 1 (2%)
Pituitary Gland (48) (49) (47) (49)
Pars Distalis, Adenoma 4 (8%) 8 (16%) 7 (15%) 5 (10%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Follicular Cell, Adenoma 5 (10%) 4 (8%) 3 (6%) 4 (8%)
Follicular Cell, Adenoma, Multiple 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (6) (4) (1)
Hemangiosarcoma 1 (17%)
Leiomyosarcoma 1 (100%)
Abdominal, Osteosarcoma 1 (17%)
Pelvic, Sarcoma 1 (25%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (41) (47) (48) (48)
Fibrosarcoma 1 (2%)
Ovary (49) (50) (49) (49)
Cystadenoma 2 (4%) 2 (4%)
Fibrosarcoma, Metastatic, Pancreas 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Uterus (50) (50) (50) (50)
Leiomyosarcoma 1 (2%)
Polyp Stromal 2 (4%) 1 (2%) 1 (2%)
Sarcoma 1 (2%)
Endometrium, Adenoma 1 (2%)
Myometrium, Hemangioma 1 (2%)
Vagina (1)
Leiomyosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 75 PPM 250 750
PPM PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (48) (50) (50) (50)
Lymph Node (3) (7) (2) (5)
Iliac, Hemangioma 1 (14%)
Lumbar, Osteosarcoma, Metastatic, Tissue NOS 1 (14%)
Renal, Hemangiosarcoma 1 (14%)
Lymph Node, Bronchial (32) (40) (29) (38)
Fibrosarcoma, Metastatic, Pancreas 1 (3%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (3%)
Lymph Node, Mandibular (47) (48) (47) (44)
Lymph Node, Mesenteric (48) (48) (46) (44)
Fibrosarcoma, Metastatic, Pancreas 1 (2%)
Lymph Node, Mediastinal (34) (42) (41) (31)
Fibrosarcoma, Metastatic, Pancreas 1 (3%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (3%)
Spleen (50) (50) (50) (49)
Capsule, Fibrosarcoma, Metastatic, Pancreas 1 (2%)
Thymus (42) (44) (45) (46)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (50) (48) (49)
Carcinoma 1 (2%) 3 (6%)
Skin (50) (50) (49) (50)
Fibroma 1 (2%)
Fibrosarcoma 2 (4%)
Fibrous Histiocytoma 1 (2%)
Hemangioma 1 (2%) 2 (4%)
Squamous Cell Carcinoma 1 (2%)
Sebaceous Gland, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (49) (50) (50) (50)
Rib, Sarcoma, Metastatic, Tissue NOS 1 (2%)
Vertebra, Osteosarcoma 1 (2%)
Skeletal Muscle (2)
Carcinoma, Metastatic, Mammary Gland 1 (50%)
Rhabdomyosarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 75 PPM 250 750
PPM PPM
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Cerebrum, Oligodendroglioma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (49) (49) (47) (48)
Lung (50) (50) (49) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 4 (8%) 4 (8%) 8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 1 (2%) 2 (4%) 1 (2%)
Osteosarcoma, Metastatic, Tissue NOS 1 (2%)
Sarcoma, Metastatic, Tissue NOS 1 (2%)
Sarcoma, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Lacrimal Gland 1 (2%)
Nose (49) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Pleura (1)
Hepatocellular Carcinoma, Metastatic, Liver 1 (100%)
Trachea (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (1) (3)
Adenoma 1 (100%) 3 (100%)
Carcinoma 1 (100%)
Lacrimal Gland (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Cortex, Fibrosarcoma, Metastatic, Pancreas 1 (2%)
Ureter (1) (1)
Urinary Bladder (47) (48) (47) (49)
Page 5
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 75 PPM 250 750
PPM PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Serosa, Sarcoma, Metastatic, Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Leukemia Granulocytic 1 (2%)
Lymphoma Malignant 3 (6%) 6 (12%) 5 (10%) 5 (10%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 75 PPM 250 750
PPM PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 29 38 31 38
Total Primary Neoplasms 44 58 50 60
Total Animals with Benign Neoplasms 20 26 27 28
Total Benign Neoplasms 27 34 39 40
Total Animals with Malignant Neoplasms 13 20 9 18
Total Malignant Neoplasms 17 24 11 20
Total Animals with Metastatic Neoplasms 5 5 3 2
Total Metastatic Neoplasm 18 9 4 2
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 250 750
PPM PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 6 2 5 6
Natural Death 15 12 13 13
Accidently Killed 1 1
Survivors
Terminal Sacrifice 28 36 31 30
Natural Death 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (42) (46) (44) (43)
Intestine Small, Jejunum (44) (46) (44) (43)
Epithelium, Carcinoma 1 (2%)
Intestine Small, Ileum (42) (46) (44) (41)
Liver (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Cholangiocarcinoma 1 (2%)
Fibrosarcoma, Metastatic, Stomach, Glandular 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 17 (34%) 8 (16%) 11 (22%) 10 (20%)
Hepatocellular Carcinoma, Multiple 1 (2%) 2 (4%)
Hepatocellular Adenoma 11 (22%) 12 (24%) 17 (34%) 17 (34%)
Hepatocellular Adenoma, Multiple 1 (2%) 4 (8%) 1 (2%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%) 1 (2%)
Mesentery (1) (1)
Hepatocellular Carcinoma, Metastatic, Liver 1 (100%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
Pancreas (49) (50) (48) (48)
Acinus, Hepatocholangiocarcinoma, Metastatic,
Liver 1 (2%)
Stomach, Forestomach (48) (50) (50) (47)
Fibrosarcoma, Metastatic, Stomach, Glandular 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (48) (50) (50) (47)
Fibrosarcoma 1 (2%)
Tooth (1) (1)
Odontoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 250 750
PPM PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (48) (48) (49) (47)
Aorta, Fibrosarcoma, Metastatic, Stomach,
Glandular 1 (2%)
Aorta, Hepatocellular Carcinoma, Metastatic,
Liver 1 (2%)
Aorta, Sarcoma 1 (2%)
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Fibrosarcoma, Metastatic, Stomach, Glandular 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Pericardium, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (47) (47) (48) (48)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Islets, Pancreatic (49) (50) (48) (48)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (44) (45) (45) (47)
Pars Distalis, Carcinoma 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Follicular Cell, Adenoma 3 (6%) 2 (4%) 1 (2%) 5 (10%)
Follicular Cell, Adenoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (2) (3) (1) (2)
Fibrosarcoma 1 (50%)
Fat, Hepatocholangiocarcinoma, Metastatic,
Liver 1 (100%)
Thoracic, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (50%)
Thoracic, Sarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 250 750
PPM PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (50) (50) (50)
Leiomyoma 1 (2%)
Seminal Vesicle (49) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Testes (49) (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Lymph Node (4) (7) (11) (3)
Fibrosarcoma, Metastatic, Stomach, Glandular 1 (25%)
Pancreatic, Carcinoma 1 (33%)
Popliteal, Hemangioma 1 (9%)
Renal, Cholangiocarcinoma, Metastatic, Liver 1 (14%)
Renal, Fibrosarcoma, Metastatic, Stomach,
Glandular 1 (25%)
Renal, Hepatocholangiocarcinoma, Metastatic,
Liver 1 (9%)
Lymph Node, Bronchial (14) (24) (27) (27)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (4%)
Fibrosarcoma, Metastatic, Stomach, Glandular 1 (7%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (4%)
Sarcoma 1 (4%)
Lymph Node, Mandibular (43) (45) (46) (44)
Sarcoma, Metastatic, Nose 1 (2%)
Lymph Node, Mesenteric (45) (46) (47) (48)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Lymph Node, Mediastinal (24) (25) (27) (25)
Fibrosarcoma, Metastatic, Stomach, Glandular 1 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (4%)
Sarcoma 1 (4%)
Spleen (50) (50) (49) (49)
Thymus (37) (37) (39) (34)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Sarcoma 1 (3%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 250 750
PPM PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Fibrosarcoma 1 (2%)
Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (49) (50) (50)
Sternum, Fibrosarcoma, Metastatic, Stomach,
Glandular 1 (2%)
Skeletal Muscle (2) (2)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (50%)
Fibrosarcoma, Metastatic, Stomach, Glandular 1 (50%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (50%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 5 (10%) 8 (16%) 9 (18%) 15 (30%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%) 5 (10%) 3 (6%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibrosarcoma, Metastatic, Stomach, Glandular 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 5 (10%) 3 (6%) 5 (10%) 3 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) 1 (2%)
Bronchiole, Polyp Adenomatous 1 (2%)
Mediastinum, Sarcoma 1 (2%)
Nose (50) (50) (50) (50)
Sarcoma 1 (2%)
Pleura (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (100%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 250 750
PPM PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (3) (2)
Adenoma 1 (50%) 3 (100%) 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%) 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibrosarcoma, Metastatic, Stomach, Glandular 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Renal Tubule, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Leukemia Granulocytic 1 (2%) 1 (2%)
Lymphoma Malignant 2 (4%) 2 (4%) 3 (6%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05210-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLBENZENE Date: 04/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:10:56
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 75 PPM 250 750
PPM PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 34 40 41
Total Primary Neoplasms 50 49 60 68
Total Animals with Benign Neoplasms 20 25 26 30
Total Benign Neoplasms 24 33 35 43
Total Animals with Malignant Neoplasms 21 15 21 16
Total Malignant Neoplasms 26 16 25 25
Total Animals with Metastatic Neoplasms 9 4 6 5
Total Metastatic Neoplasm 28 7 17 10
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------